PGT-A results between the GH and control groups
REGRESSION
There was no significant difference in the biopsy cycle rates between the two groups (Table 
PGT-A cycle outcome of women in the GH and control groups after PSMNo. of OS cycles obtaining no blastocysts,n (%)32(22.86)68(25.00)a. Pearson’s chi-square test was used to compare the between group difference of the number of the denoted row and the sum of the other two rows. The results were presented as p-value, odds ratio (95% confidence intervals). GH = growth hormone; OS = ovarian stimulation; PGT-A = preimplantation genetic screening; PSM = propensity score matchingSubgroup analyses indicated that for patients aged 38–40 years, the proportion of cycles with euploid blastocysts (66.67% vs. 43.59%, P = 0.00), the euploid rate of blastocysts per embryo biopsied (50.58.47% vs. 29.01%, P = 0.02), the mean blastocyst euploid rate calculated per OS cycle (0.40 ± 0.37 vs. 0.24 ± 0.33, P = 0.01) and per biopsy cycle (0.46 ± 0.37 vs. 0.31 ± 0.35, P = 0.01) were significantly higher in the GH group than those in the control group. However, the benefit of GH on these outcome parameters was not significant in patients aged 41–43 years and 44–46 years (Table 
Subgroup analyses of PGT-A outcomes between the GH and control groups after PSMAge 44–46 years(n = 71)* Data are presented as number of cycles with obtained euploid blastocysts/number of OS cycles, (%)GH = growth hormone; OR = odds ratio; CI = confidence intervalMultivariate logistic regression analyses showed that GH supplementation was an independent factor in improving the acquisition of euploid embryos in patients with AMA aged 38–46 years (adjusted risk ratio [aRR] = 2.273, P = 0.001). Stratified analyses indicated the significant benefit ofGH supplementation was more pronounced in women aged 38–40 years (aRR = 2.653, P = 0.006). However, there was no association between GH supplementation and the acquisition of euploid embryos in patients aged41–43 years and 44–46 years (Table 
Logistic regression analyses of variables associated with the acquisition of euploid embryos**Confounders including GH supplement, age, AMH, AFC, BMI, number of previous OS cycles, duration of stimulation, total dosage of gonadotropins, and estradiol on trigger day, were evaluated using multivariate logistic regression models (backward LR). Covariates were retained in the final adjusted model if they were significantly associated with the outcome parameters (P < 0.05). For the subgroup of women aged 44–46 years, none of the aforementioned variables were significantly associated with the acquisition of euploid embryos; therefore, they are not presented in the table. GH = growth hormone; OR = odds ratio; CI = Confidence interval; AFC = antral follicle count; BMI = body mass index; AMH = anti-Mullerian hormone; OS = ovarian stimulation